Sector News

KKR to invest in Arbor Pharmaceuticals: sources

December 5, 2014
Life sciences
(Reuters) – KKR & Co LP has agreed to acquire a significant minority stake in Arbor Pharmaceuticals LLC, in a deal that values the privately held specialty drugmaker at more than $1 billion, including debt, people familiar with the matter said on Thursday.
 
KKR, a New York-based private equity firm, will own more than a quarter of Arbor Pharmaceuticals under the terms of the deal, the people said, asking not to be identified ahead of an official announcement.
 
KKR declined to comment. An Arbor Pharmaceuticals spokesman did not immediately respond to a request for comment.
 
Based in Atlanta, Georgia, Arbor makes mainly branded prescription drugs for the pediatric, hospital and cardiovascular markets. It offers 16 products and has more than 40 in development, according to its website.
 
Reuters reported in October that Arbor was working with investment bank JPMorgan Chase & Co (JPM.N) on strategic alternatives, including a possible sale.
 
Arbor’s existing shareholders include Chairman Jason Wild, who runs hedge fund firm JW Asset Management LLC; Chief Executive Ed Shutter; investment firm Signet Healthcare Partners LLC; and Allen Chao, co-founder and former chief executive of Watson Pharmaceuticals Inc.
 
Buyout appetite from large pharmaceutical companies and private equity firms has pushed dealmaking in the healthcare sector to record levels this year. Global healthcare volume topped $364.8 billion as the number of announced deals doubled year-to-date, according to Thomson Reuters data.
 
Arbor is the latest minority pharmaceutical investment of KKR this year. In May, KKR took a minority stake in biotherapeutics company Coherus BioSciences Inc. Coherus went public last month last month in an $85 million initial public offering.
 
KKR’s current health care investments also include contract research organization PRA Health Sciences Inc and hospital operator HCA Holdings Inc.
 
(Reporting by Greg Roumeliotis and Olivia Oran in New York; Editing by David Gregorio)

comments closed

Related News

February 7, 2025

Trump’s tariffs could strain medicine supply and drive drug costs

Life sciences

The last few days have been a rollercoaster for the pharmaceutical industry. Mexico and Canada were bracing themselves for the effects of double-digit tariffs from the US, only for President Donald Trump to pause the levies after striking a deal with the two countries.

February 7, 2025

BD announces intent to separate Biosciences and Diagnostic Solutions business

Life sciences

BD (Becton, Dickinson and Company), a leading global medical technology company, announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation.

February 7, 2025

Jabil acquires CDMO Pharmaceutics International

Life sciences

Jabil, a global provider of engineering, manufacturing, and supply chain solutions, has acquired Pharmaceutics International (Pii), a US contract development and manufacturing organization (CDMO) specializing in early-stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing.

How can we help you?

We're easy to reach